Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 4/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28203578 | 0.97 | CA2 (0.47) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL786600 | 0.97 | CA2 (0.47) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL786630 | 0.97 | CA2 (0.47) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL28657823 | 0.97 | CA2 (0.47) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL2916092 | 0.95 | CA2 (0.48) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL22019 | 0.95 | CA2 (0.48) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL2910640 | 0.95 | CA2 (0.48) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL1457564 | 0.95 | CA2 (0.48) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL3055923 | 0.92 | CA2 (0.47) | CA2CA4TDP1SMN1; SMN2SLC22A6 | |
| SCHEMBL9983146 | 0.92 | CA2 (0.47) | CA2CA4TDP1SMN1; SMN2SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389353-B1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LTD (GB) | 2017-03-08 | — | — | EP | claimed |
| US-8801962-B2 | Chelating agents and methods relating thereto | INNOSPEC LIMITED (GB) | 2014-08-12 | — | — | US | claimed |
| US-20120068113-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| EP-2389353-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | Innospec Limited (GB) | 2011-11-30 | — | — | EP | claimed |
| US-8039831-B2 | Electronic device containing semiconductor polymers and corresponding manufacturing process | MICRON TECHNOLOGY, INC. | 2011-10-18 | — | — | US | claimed |
| WO-2010084351-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2010-07-29 | — | — | WO | claimed |
| EP-2389353-B1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-8801962-B2 | Chelating agents and methods relating thereto | INNOSPEC LIMITED (GB) | 2014-08-12 | — | — | US | disclosed |
| US-20120068113-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| EP-2389353-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | Innospec Limited (GB) | 2011-11-30 | — | — | EP | disclosed |
| US-8039831-B2 | Electronic device containing semiconductor polymers and corresponding manufacturing process | MICRON TECHNOLOGY, INC. | 2011-10-18 | — | — | US | disclosed |
| WO-2010084351-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | INNOSPEC LIMITED (GB) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120068113-A1 | CHELATING AGENTS AND METHODS RELATING THERETO | SLC30A5, AOC1, SLC25A13 | CA2 5/4885CA4 26/4885TDP1 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.